Total Payments
$37,446
2024 Payments
$16,884
Companies
41
Transactions
332
Medicare Patients
1,511
Medicare Billing
$710,648
Payment Breakdown by Category
Consulting$23,085 (61.6%)
Travel$7,232 (19.3%)
Food & Beverage$6,802 (18.2%)
Other$314.67 (0.8%)
Education$12.16 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $23,085 | 10 | 61.6% |
| Travel and Lodging | $7,232 | 14 | 19.3% |
| Food and Beverage | $6,802 | 305 | 18.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $314.67 | 2 | 0.8% |
| Education | $12.16 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $20,990 | 54 | $0 (2024) |
| Lilly USA, LLC | $8,213 | 30 | $0 (2024) |
| LivaNova USA, Inc. | $1,611 | 4 | $0 (2019) |
| OnMark, Inc. | $1,400 | 1 | $0 (2024) |
| ABBVIE INC. | $1,293 | 95 | $0 (2024) |
| VERTEX PHARMACEUTICALS INCORPORATED | $425.00 | 1 | $0 (2024) |
| Biogen, Inc. | $271.21 | 7 | $0 (2021) |
| Lundbeck LLC | $255.28 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $245.05 | 11 | $0 (2024) |
| Corium, LLC | $211.63 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,884 | 120 | Lilly USA, LLC ($7,813) |
| 2023 | $15,281 | 121 | Eisai Inc. ($13,531) |
| 2022 | $906.00 | 51 | Janssen Pharmaceuticals, Inc ($184.16) |
| 2021 | $1,870 | 7 | Eisai Inc. ($1,650) |
| 2020 | $204.76 | 11 | ACADIA Pharmaceuticals Inc ($61.65) |
| 2019 | $2,071 | 20 | LivaNova USA, Inc. ($1,611) |
| 2018 | $228.21 | 2 | Allergan Inc. ($117.04) |
All Payment Transactions
332 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: EPILEPSY | ||||||
| 12/17/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $32.06 | General |
| Category: Neurology | ||||||
| 12/16/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 12/12/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $16.15 | General |
| 12/11/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Insomnia | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $5,800.00 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | Lilly USA, LLC | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Neuroscience | ||||||
| 11/25/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Neurology | ||||||
| 11/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $430.23 | General |
| 11/13/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: PAIN | ||||||
| 11/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: Neurology | ||||||
| 11/06/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Neuroscience | ||||||
| 10/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: NEUROSCIENCE | ||||||
| 10/07/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: Neurology | ||||||
| 09/25/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Neurology | ||||||
| 09/17/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 765 | 100,101 | $1.6M | $539,519 |
| 2022 | 11 | 354 | 8,894 | $434,457 | $125,166 |
| 2021 | 5 | 169 | 186 | $77,730 | $23,608 |
| 2020 | 4 | 223 | 248 | $80,662 | $22,355 |
Total Patients
1,511
Total Services
109,429
Medicare Billing
$710,648
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 92 | 33,796 | $925,556 | $312,583 | 33.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 4,320 | $220,273 | $80,476 | 36.5% |
| J0174 | Injection, lecanemab-irmb, 1 mg | Office | 2023 | 26 | 61,116 | $183,300 | $64,156 | 35.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 95 | 219 | $81,489 | $21,817 | 26.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 39 | 39 | $33,272 | $10,768 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 80 | $41,920 | $10,752 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 64 | 64 | $41,132 | $9,740 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 98 | $36,724 | $8,882 | 24.2% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 35 | 35 | $21,750 | $6,992 | 32.1% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 53 | 59 | $17,212 | $5,933 | 34.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 19 | 73 | $13,213 | $3,593 | 27.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 54 | 60 | $4,482 | $1,522 | 33.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 94 | 124 | $5,169 | $1,319 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 18 | $5,307 | $987.08 | 18.6% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2022 | 26 | 8,520 | $289,680 | $79,207 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 65 | 65 | $42,250 | $11,463 | 27.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 37 | 37 | $27,528 | $11,008 | 40.0% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 28 | 28 | $16,240 | $5,960 | 36.7% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 42 | 45 | $9,716 | $4,679 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 48 | $17,841 | $4,456 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 25 | $13,000 | $3,622 | 27.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $6,720 | $1,761 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 17 | $6,220 | $1,237 | 19.9% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2022 | 43 | 46 | $2,420 | $1,214 | 50.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 28 | 49 | $2,842 | $557.89 | 19.6% |
About Samuel Giles
Samuel Giles is a Internal Medicine healthcare provider based in Jacksonville Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/26/2015. The National Provider Identifier (NPI) number assigned to this provider is 1427430370.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Samuel Giles has received a total of $37,446 in payments from pharmaceutical and medical device companies, with $16,884 received in 2024. These payments were reported across 332 transactions from 41 companies. The most common payment nature is "Consulting Fee" ($23,085).
As a Medicare-enrolled provider, Giles has provided services to 1,511 Medicare beneficiaries, totaling 109,429 services with total Medicare billing of $710,648. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology
- Location Jacksonville Beach, FL
- Active Since 06/26/2015
- Last Updated 07/15/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427430370
Products in Payments
- Leqembi (Drug) $19,272
- KISUNLA (Drug) $7,219
- VNS Therapy (Device) $1,611
- UBRELVY (Drug) $807.05
- QULIPTA (Drug) $486.28
- AMYVID (Drug) $298.92
- VYEPTI (Biological) $255.28
- NURTEC ODT (Drug) $242.58
- EMGALITY (Drug) $222.00
- Adlarity (Drug) $211.63
- NUPLAZID (Drug) $209.04
- KESIMPTA (Drug) $199.65
- Ponvory (Drug) $184.16
- ADUHELM (Biological) $168.39
- Aimovig (Biological) $161.98
- BOTOX (Biological) $130.39
- GOCOVRI (Drug) $111.17
- SOLIRIS (Drug) $106.67
- Trudhesa (Drug) $102.62
- REXULTI (Drug) $97.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville Beach
Dr. Anthony Capasso, M.d, M.D
Internal Medicine — Payments: $7,400
Internal Medicine $7,400
Dr. George Dibu, M.d, M.D
Internal Medicine — Payments: $6,297
Internal Medicine $6,297
Robert Bass, Md, MD
Internal Medicine — Payments: $5,610
Internal Medicine $5,610
Amer Shahla, Md, MD
Internal Medicine — Payments: $1,976
Internal Medicine $1,976
Graciela Diez-Hoeck, Md, MD
Internal Medicine — Payments: $1,871
Internal Medicine $1,871
Sean Shahla, Md, MD
Internal Medicine — Payments: $1,766
Internal Medicine $1,766